Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $43.14

Key Points

• Arrowhead Pharmaceuticals has received a consensus rating of "Buy" from analysts, with an average 1-year price target of $43.14.
• The company reported a loss of ($1.26) EPS for the last quarter, which was below analysts' expectations, coupled with revenue of $27.77 million.
• Insider transactions revealed that James C. Hamilton sold 15,000 shares at a price of $30.00, reducing his ownership by 6.07%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has received an average rating of "Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $43.1429.

ARWR has been the subject of a number of analyst reports. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Finally, Royal Bank Of Canada dropped their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Friday, August 8th.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 15,000 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $30.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider owned 232,122 shares in the company, valued at approximately $6,963,660. This represents a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 40,000 shares of company stock valued at $1,025,000. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock valued at $168,201,000 after purchasing an additional 1,018,273 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after acquiring an additional 2,774,933 shares during the last quarter. Geode Capital Management LLC grew its position in Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company's stock valued at $47,067,000 after acquiring an additional 28,193 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company's stock valued at $32,220,000 after purchasing an additional 21,686 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Down 2.6%

ARWR stock traded down $0.82 during midday trading on Thursday, hitting $30.69. The stock had a trading volume of 4,937,943 shares, compared to its average volume of 2,821,898. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $31.67. The company's 50-day moving average price is $21.17 and its 200 day moving average price is $16.94. The firm has a market cap of $4.24 billion, a PE ratio of -23.98 and a beta of 1.00. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to analysts' expectations of $29.01 million. During the same quarter last year, the business posted ($1.38) EPS. On average, equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.